Compass Therapeutics (CMPX) PT Lowered to $7 at Jefferies

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. AVGO
2. CDNS
3. SPY
4. META
5. JBLU
6. ANT
7. SSD
8. ARTV
9. AAPL
10. INTC

Go back to Compass Therapeutics (CMPX) PT Lowered to $7 at Jefferies

Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update

May 13, 2024 8:00 AM EDT

Received FDA Fast Track Designation for the investigation of CTX-009 in combination with paclitaxel for the treatment of patients with metastatic or locally advanced biliary tract tumors. Enrollment is progressing well in COMPANION-002, a Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC). Enrollment is expected to be completed by mid-year 2024 with top-line data expected in the first quarter of 2025.Completed enrollment of patients in COMPANION-003, a Phase 2 study of CTX-009 in patients with... More